(Nasdaq: NRXP) Hits Our Watchlist With 6 Key Potential Catalysts (Oversold Leaning Technicals)

Regulatory paperwork rarely makes headlines.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: NRXP) Hits Our Watchlist With 6 Key Potential Catalysts (Oversold Leaning Technicals) *Click Here To Get Our Alerts Faster Via SMS* October 19th Greetings Readers, Regulatory paperwork rarely makes headlines. A labeling letter from the FDA is about as dry as agency mail gets. Yet for NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a review letter disclosed in mid-October may be the clearest sign yet that a long regulatory climb is nearing the summit. The FDA asked for minor changes only. Its main request was simple: submit sample labeling with the proposed brand name ahead of the November 10th, 2026 GDUFA goal date for the company's preservative-free ket-a-mine. That date did not appear by accident. The FDA's generic review office found only minor quality items in April, following a favorable bioequivalence determination in March. In September, the agency reclassified a vial-related amendment from major to minor and moved the goal date up to November 10th. Why does a preservative matter? Existing ket-a-mine products contain ben-ze-thonium chloride, a preservative no longer permitted in new formulations under FDA policy. NRx's version leaves it out, and the company points to physician-documented supply shortages as a reason the product is important. NRx is not waiting idly. Management has ordered 5Mn units of launch inventory and appointed its first Chief Commercial Officer, with planned capacity of 1Mn units per month after launch. The balance sheet has changed shape, too. Cash stood at approx. $26.7Mn on June 30th, up from $7.8Mn at year-end 2025, according to the company's second-quarter results. The first-half net loss narrowed to $18.0Mn from $23.1Mn a year earlier. Six steps on the preservative-fr-ee ket-a-mine review path. Graphic built from company releases and SEC filings. Behind The Scenes: The August Earnings Call NRx's second-quarter call played less like a status update and more like a launch briefing. NRx CEO Dr. Jonathan Javitt opened by calling the quarter “a major inflection point” for the company. The sharpest exchange came during Q&A. BTIG analyst Tom Schrader asked how the generic ket-a-mine, branded KETAFREE, would launch alongside the depression programs. Javitt drew a clean line: separate products, separate product codes and separate commercial paths. The KETAFREE label, he said, will not include depression. NRx CFO Michael Abrams then addressed the cash question head on. He told listeners current resources should support operations for at least a year, following a public offering with gross proceeds of more than $22Mn. The Pivot: From Pharmacy Shelf To Defense Lab The quarter's most strategic move happened outside the pharmacy. NRx formed NRx Defense Systems, a Florida subsidiary built to pair low-dose D-cycloserine, a key ingredient in NRX-101, with transcranial magnetic stimulation (TMS). That strategy now has federal backing. DARPA a-warded the subsidiary a prime contract worth approx. $11.2Mn to run SPARC-TMS, a randomized Phase II/III study of up to 400 adults with treatment-resistant depression. Patients receive robot-guided TMS over a single day plus five days of NRX-101. The design builds on published real-world findings of 91% treatment response and 69% remission at three months using traditional TMS with D-cycloserine. Partners include Harvard Medical School's McLean Hospital, Arizona State University and Zeta Surgical. If earlier results hold, NRx says the study could potentially support a future FDA filing for NRX-101. About NRx Pharmaceuticals, Inc. NRx is a clinical-stage biopharmaceutical company built on an NMDA platform for depression, suicidality, PTSD, and chronic pain. Its pipeline runs on three product tracks: KETAFREE is the preservative-free ket-a-mine under review through the generic (ANDA) pathway for the existing anesthesia label. NRX-100 is preservative-free IV ket-a-mine with Fast Track designation; after a Type C meeting, the FDA requested no additional trials for a planned application in severe depression. NRX-101, an oral D-cycloserine and lurasidone combination, holds Breakthrough Therapy Designation for suicidal bipolar depression. Revenue today comes from HOPE Therapeutics, the clinic subsidiary. The latest 10-Q shows HOPE operating six Florida locations offering ket-a-mine infusion, TMS and Spravato, built partly through the Dura Medical acquisition and the purchase of KMD Wellness clinic assets in Boca Raton. Patient service revenue reached approx. $2.2Mn in the first half of 2026. More Sources: NRXP Website. 6 Potential Catalysts Carry (Nasdaq: NRXP) To Our Top Watchlist Spot #1. A Federal Goal Date Is Now Firmly On The Calendar. The FDA has set November 10th, 2026 as the GDUFA goal date for the preservative-fr-ee ket-a-mine application from NRx NRXP, following a request for only minor labeling changes. #2. Launch Inventory Is Already Ordered And Waiting. Management says NRXP has ordered 5Mn units of launch inventory ahead of a potential approval decision. #3. Non-Dilutive DARPA Funding Backs A Potential Registration Trial. The approx. $11.2Mn SPARC-TMS contract gives NRXP federal funding for a study the company says could potentially support a future NRX-101 filing. #4. An FDA Path For NRX-100 Without New Trials. FDA meeting minutes indicate NRXP can pursue its NRX-100 application using existing controlled trial data plus real-world evidence. #5. Analyst Coverage Points To Significant Targets. 2026 ratings on NRXP tracked by Benzinga are positive, with Ascendiant Capital raising its target to $50 on October 1st and a five-analyst consensus near $30. #6. Multiple Technical Indicators Flashing Oversold Signals. At close on Friday, Barchart was reporting multiple technical indicators to be flashing oversold signals for NRXP including a 9-Day and 14-Day Relative Strength Index both below 31%. The Bottom Line NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has spent years building toward one regulatory moment, and that moment now has a date. Add a DARPA-funded trial, a Florida clinic network, and a stronger balance sheet, and NRXP carries more moving parts than a quick glance suggests. It also lists an expected earnings date of November 12th, just two days after the goal date. We’re initiating coverage on NRx Pharmaceuticals, Inc. (Nasdaq: NRXP). Be on the lookout for updates coming out soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 10/18/2026 and ending on 10/19/2026 to publicly disseminate information about (NRXP:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the forty thousand USD funds that TD Media LLC received from a third party named DMS Consulting LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (NRXP:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/nrxp-teshw/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice

"This is the Perfect Tech Stock" 🟢

And I predict it will be the next big AI winner —  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Unsubscribe  Market Signal | New Investment Opportunity from Jeff Brown   Editor's Note: Jeff Brown is the former tech executive who picked Nvidia in 2016 before it jumped 37,000% higher. He’s now recommending another AI stock that’s the same size Nvidia was 10 years ago. He calls it “Elon Musk’s One Stock Retirement Plan” because he believes Elon Musk is about to create massive demand for this company’s patented technology. Go here to see the details or read more below — Dear Friend, I just found what I believe is the perfect tech stock… It checks all the boxes I look for in potential home runs… #1- It’s a leader in a tech breakthrough that could change the world… Its patented tech can produce intelligence up to 1,000 times FASTER than regular AI. #2- This AI breakthrough is protected by 150 patents… Meaning no other company can do what they do. #3- This stock is entering a phase of exponential growth… With Wall Street projecting sales to more than triple in the coming year. #4- It’s a relatively small company, unknown to most people… Which means there’s a ton of upside potential. In fact, this company is about the same size Nvidia was back in 2016… Before it exploded 37,800% higher... And while I can’t guarantee you’ll become a millionaire... That was enough to turn $5,000 into an entire retirement nest egg of $1,895,000. And last but not least… #5 It has a catalyst on November 11 that could send shares skyrocketing. Go here to see the details before it’s too late. We have so much to look forward to, Jeff Brown, Founder & CEO, Brownstone Research P.S. I call this opportunity “Elon Musk’s One Stock Retirement Plan.” Why? Because Elon Musk just made two moves that I believe will create massive demand for this company’s patented technology. And I believe if you buy shares of this company BEFORE the upcoming announcement from its executive team… This single investment could potentially be your ticket to retirement.   - a sponsored message from Brownstone Research - Thank you for subscribing to Market Briefing, the 7am ET briefing that curates top headlines and stories impacting the markets each day. This message is a paid advertisement sent on behalf of a third-party advertiser of Market Briefing. If you have questions about your subscription, please contact us via email at vip@marketbriefing.com If you no longer wish to receive email from Market Briefing you can unsubscribe here.   Update your email preferences or unsubscribe here © 2026 Market Briefing, a Capital Media Agency publication 99 Wall St, Ste 314 New York, NY 10005, United States